Article
Clinical features, genetics, treatment, and long-term outcomes of STAT3 hyper-IgE syndrome: Single-center cohort analysis.
The Journal of allergy and clinical immunology - 1 Aug 2026
Freeman Alexandra F, Wang Chen, Urban Amanda, Martin Iris, Dang Lauren, Davis Joie, Bergerson Jenna R E, Ali Sania, An Zixiao Annie, Patel Meera, Williamson Hastings, Marciano Beatriz E, Lafeer Christine, Roy Susan, Ulrick Jean, Heller Theo, Sharma Disha, Castelo-Soccio Leslie, Cowen Edward W, Kong Heidi H, Gupta Sarthak, Ghosh Rajarshi, Seifert Bryce A, Tokita Mari J, Walkiewicz Magdalena A, Similuk Morgan, Stoddard Jennifer, Rosenzweig Sergio D, Matta Jatin Raj, Gharib Ahmed M, Jahanmir Golnar, Brenchley Laurie, Shastri Kalpakam, Moutsopoulos Niki M, Kitani Takashi, Arnold Danielle E, Dimitrova Dimana, Gonzalez Corina E, Pai Sung-Yun, Malech Harry L, Gallin John I, Fennelly Kevin, Olivier Kenneth N, Mackie Joseph, Tangye Stuart G, Hsu Amy P, Milner Joshua D, Heimall Jennifer, Holland Steven M
Abstract excerpt
BACKGROUND: Signal transducer and activator of transcription 3 hyper-IgE syndrome (STAT3-HIES) is a multisystem disorder with both immunologic and nonimmunologic manifestations. OBJECTIVE: We sought to characterize the spectrum of clinical manifestations, genetics, treatment approaches, and long-term outcomes of patients with STAT3-HIES. METHODS: Clinical features, laboratory findings, treatment, and survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.